GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Enveric Biosciences Inc (STU:SLZA) » Definitions » EV-to-FCF

Enveric Biosciences (STU:SLZA) EV-to-FCF : 0.09 (As of Jun. 04, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Enveric Biosciences EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Enveric Biosciences's Enterprise Value is €-1.00 Mil. Enveric Biosciences's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 was €-10.69 Mil. Therefore, Enveric Biosciences's EV-to-FCF for today is 0.09.

The historical rank and industry rank for Enveric Biosciences's EV-to-FCF or its related term are showing as below:

STU:SLZA' s EV-to-FCF Range Over the Past 10 Years
Min: -69.46   Med: -4.99   Max: 0.37
Current: 0.08

During the past 13 years, the highest EV-to-FCF of Enveric Biosciences was 0.37. The lowest was -69.46. And the median was -4.99.

STU:SLZA's EV-to-FCF is ranked better than
93.39% of 378 companies
in the Biotechnology industry
Industry Median: 8.345 vs STU:SLZA: 0.08

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-06-04), Enveric Biosciences's stock price is €0.703. Enveric Biosciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was €-5.933. Therefore, Enveric Biosciences's PE Ratio for today is At Loss.


Enveric Biosciences EV-to-FCF Historical Data

The historical data trend for Enveric Biosciences's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Enveric Biosciences EV-to-FCF Chart

Enveric Biosciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -4.00 -10.54 -1.06 0.70 -0.09

Enveric Biosciences Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.45 -0.01 -0.06 -0.09 -0.08

Competitive Comparison of Enveric Biosciences's EV-to-FCF

For the Biotechnology subindustry, Enveric Biosciences's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Enveric Biosciences's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Enveric Biosciences's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Enveric Biosciences's EV-to-FCF falls into.



Enveric Biosciences EV-to-FCF Calculation

Enveric Biosciences's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=-1.002/-10.685
=0.09

Enveric Biosciences's current Enterprise Value is €-1.00 Mil.
Enveric Biosciences's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-10.69 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Enveric Biosciences  (STU:SLZA) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Enveric Biosciences's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.703/-5.933
=At Loss

Enveric Biosciences's share price for today is €0.703.
Enveric Biosciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-5.933.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Enveric Biosciences EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Enveric Biosciences's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Enveric Biosciences (STU:SLZA) Business Description

Traded in Other Exchanges
Address
4851 Tamiami Trail N, Suite 200, Naples, FL, USA, 34103
Enveric Biosciences Inc is a patient-centric biotechnology company focused on developing new-generation, naturally occurring chemical compounds, such as cannabinoids to improve the lives of those who are adversely affected by the side effects of cancer treatments. Its product in the pipeline includes Glioblastoma Multiforme (GBM); Radiation Dermatitis and Chemotherapy-Induced Peripheral Neuropathy (CIPN).

Enveric Biosciences (STU:SLZA) Headlines

No Headlines